These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 17311301)
1. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301 [TBL] [Abstract][Full Text] [Related]
2. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Maranchie JK; Afonso A; Albert PS; Kalyandrug S; Phillips JL; Zhou S; Peterson J; Ghadimi BM; Hurley K; Riss J; Vasselli JR; Ried T; Zbar B; Choyke P; Walther MM; Klausner RD; Linehan WM Hum Mutat; 2004 Jan; 23(1):40-6. PubMed ID: 14695531 [TBL] [Abstract][Full Text] [Related]
3. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease. Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029 [TBL] [Abstract][Full Text] [Related]
4. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001 [TBL] [Abstract][Full Text] [Related]
5. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925 [TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860 [TBL] [Abstract][Full Text] [Related]
7. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Chen F; Kishida T; Duh FM; Renbaum P; Orcutt ML; Schmidt L; Zbar B Cancer Res; 1995 Nov; 55(21):4804-7. PubMed ID: 7585510 [TBL] [Abstract][Full Text] [Related]
9. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Shuib S; Wei W; Sur H; Morris MR; McMullan D; Rattenberry E; Meyer E; Maxwell PH; Kishida T; Yao M; Latif F; Maher ER Genes Chromosomes Cancer; 2011 Jul; 50(7):479-88. PubMed ID: 21456047 [TBL] [Abstract][Full Text] [Related]
10. Multifocal bilateral renal cell carcinoma and retinal angiomas in a patient with de novo von Hippel-Lindau disease: identification of a new germline mutation. Sessa A; Battini G; Meroni M; Pitingolo F; Righetti M; Ciotti P; Di Maria E; Bellone E; Ajmar F; Mandich P J Nephrol; 2005; 18(2):209-12. PubMed ID: 15931650 [TBL] [Abstract][Full Text] [Related]
11. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Seizinger BR; Rouleau GA; Ozelius LJ; Lane AH; Farmer GE; Lamiell JM; Haines J; Yuen JW; Collins D; Majoor-Krakauer D Nature; 1988 Mar; 332(6161):268-9. PubMed ID: 2894613 [TBL] [Abstract][Full Text] [Related]
12. [Von Hippel-Lindau disease and renal cancer: 10 years of genetic progress. GEFVHL (French-Speaking Study Group on von Hippel-Lindau disease)]. Richard S; Beroud C; Joly D; Chretien Y; Benoit G Prog Urol; 1998 Jun; 8(3):330-9. PubMed ID: 9689663 [TBL] [Abstract][Full Text] [Related]
13. Chromosome 3p deletion in a renal cell carcinoma cell line established from a patient with von Hippel-Lindau disease. Kohno T; Sekine T; Tobisu K; Oshimura M; Yokota J Jpn J Clin Oncol; 1993 Aug; 23(4):226-31. PubMed ID: 8105119 [TBL] [Abstract][Full Text] [Related]
14. Screening for renal carcinoma associated mutations in the von Hippel-Lindau tumor suppressor gene by temperature gradient gel electrophoresis. Wenzel M; Enczmann J; Uhrberg M; Hernández A; Wiese U; Ackermann R; Schmitz-Draeger B; Ebert T; Wernet P Electrophoresis; 1997 Jan; 18(1):45-51. PubMed ID: 9059819 [TBL] [Abstract][Full Text] [Related]
15. Mutations of the VHL tumour suppressor gene in renal carcinoma. Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601 [TBL] [Abstract][Full Text] [Related]
17. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067 [TBL] [Abstract][Full Text] [Related]
18. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Gnarra JR; Lerman MI; Zbar B; Linehan WM Semin Oncol; 1995 Feb; 22(1):3-8. PubMed ID: 7855617 [TBL] [Abstract][Full Text] [Related]
19. Genotype-phenotype correlations in VHL exon deletions. McNeill A; Rattenberry E; Barber R; Killick P; MacDonald F; Maher ER Am J Med Genet A; 2009 Oct; 149A(10):2147-51. PubMed ID: 19764026 [TBL] [Abstract][Full Text] [Related]
20. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]